BioSpace News Archive

CRH Medical Corporation, announced financial and operating results for the year and three months ended December 31, 2020.

IVERIC bio, Inc. reported that on March 15, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.

Havn Life Sciences Inc., a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that industry veteran Jenna Pozar is joining the team as Chief Operating Officer.

Visus Therapeutics Inc. (the “Company”), a clinical-stage pharmaceutical company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug Application (IND)

Halberd Corporation (OTC PINK:HALB) has contracted with a major nutraceutical manufacturer to produce its initial production lot of Halberds VITA-SHIELD-MAX TM Immune Booster.

Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized 25% of the 675 patients planned for its phase 3 study

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at Maxim Group 2021 Emerging Growth Virtual Conference to be held March 17-19, 2021, 9:00 AM - 5:00 PM EST.

Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, announces a collaboration with JelikaLite, a company developing Cognilum™, a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial titled “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children.”

Skye Bioscience, Inc., a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced preclinical data demonstrating that THCVHS, the Company’s novel THC prodrug, showed no signs of irritation of the eye using an in vitro assay, the EpiOcular TM MTT ET-50.